177 related articles for article (PubMed ID: 25219826)
1. Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization.
Alberti C
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2275-82. PubMed ID: 25219826
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.
Alberti C
G Chir; 2015; 36(3):133-6. PubMed ID: 26188759
[TBL] [Abstract][Full Text] [Related]
3. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.
Chang L; Graham PH; Hao J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cancer Metastasis Rev; 2014 Sep; 33(2-3):469-96. PubMed ID: 24445654
[TBL] [Abstract][Full Text] [Related]
4. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.
Skvortsova I; Skvortsov S; Stasyk T; Raju U; Popper BA; Schiestl B; von Guggenberg E; Neher A; Bonn GK; Huber LA; Lukas P
Proteomics; 2008 Nov; 8(21):4521-33. PubMed ID: 18821526
[TBL] [Abstract][Full Text] [Related]
5. Targeted radiosensitization in prostate cancer.
Ghotra VP; Geldof AA; Danen EH
Curr Pharm Des; 2013; 19(15):2819-28. PubMed ID: 23448469
[TBL] [Abstract][Full Text] [Related]
6. [Cancer stem cells, cornerstone of radioresistance and perspectives for radiosensitization: glioblastoma as an example].
Chargari C; Moncharmont C; Lévy A; Guy JB; Bertrand G; Guilbert M; Rousseau C; Védrine L; Alphonse G; Toillon RA; Rodriguez-Lafrasse C; Deutsch E; Magné N
Bull Cancer; 2012 Dec; 99(12):1153-60. PubMed ID: 23228708
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cells in prostate cancer radioresistance.
Tsao T; Beretov J; Ni J; Bai X; Bucci J; Graham P; Li Y
Cancer Lett; 2019 Nov; 465():94-104. PubMed ID: 31493443
[TBL] [Abstract][Full Text] [Related]
8. Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells.
Cojoc M; Peitzsch C; Kurth I; Trautmann F; Kunz-Schughart LA; Telegeev GD; Stakhovsky EA; Walker JR; Simin K; Lyle S; Fuessel S; Erdmann K; Wirth MP; Krause M; Baumann M; Dubrovska A
Cancer Res; 2015 Apr; 75(7):1482-94. PubMed ID: 25670168
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cells and signaling pathways in radioresistance.
Chang L; Graham P; Hao J; Ni J; Deng J; Bucci J; Malouf D; Gillatt D; Li Y
Oncotarget; 2016 Mar; 7(10):11002-17. PubMed ID: 26716904
[TBL] [Abstract][Full Text] [Related]
10. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract][Full Text] [Related]
11. Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse.
Seifert M; Peitzsch C; Gorodetska I; Börner C; Klink B; Dubrovska A
PLoS Comput Biol; 2019 Nov; 15(11):e1007460. PubMed ID: 31682594
[TBL] [Abstract][Full Text] [Related]
12. 5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Begg AC; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1515-23. PubMed ID: 21944462
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization of hormone-refractory prostate cancer cells by gossypol treatment.
Akagunduz O; Karaca B; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Haydaroglu A; Uslu R
J BUON; 2010; 15(4):763-7. PubMed ID: 21229643
[TBL] [Abstract][Full Text] [Related]
14. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.
Potiron VA; Abderrahmani R; Giang E; Chiavassa S; Di Tomaso E; Maira SM; Paris F; Supiot S
Radiother Oncol; 2013 Jan; 106(1):138-46. PubMed ID: 23321494
[TBL] [Abstract][Full Text] [Related]
16. IMRT and molecular biological approaches in radiotherapy for prostate cancer.
Bristow RG
Eur J Cancer; 2009 Sep; 45 Suppl 1():429-30. PubMed ID: 19775659
[No Abstract] [Full Text] [Related]
17. CXCR4 as biomarker for radioresistant cancer stem cells.
Trautmann F; Cojoc M; Kurth I; Melin N; Bouchez LC; Dubrovska A; Peitzsch C
Int J Radiat Biol; 2014 Aug; 90(8):687-99. PubMed ID: 24650104
[TBL] [Abstract][Full Text] [Related]
18. Targeting a cornerstone of radiation resistance: cancer stem cell.
Moncharmont C; Levy A; Gilormini M; Bertrand G; Chargari C; Alphonse G; Ardail D; Rodriguez-Lafrasse C; Magné N
Cancer Lett; 2012 Sep; 322(2):139-47. PubMed ID: 22459349
[TBL] [Abstract][Full Text] [Related]
19. Targeting MicroRNAs in Prostate Cancer Radiotherapy.
Ni J; Bucci J; Chang L; Malouf D; Graham P; Li Y
Theranostics; 2017; 7(13):3243-3259. PubMed ID: 28900507
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
